A First –in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3.

A phaSe 1/2 trial of EO2401, a novel microbial-derived Peptide therapeutic vaccine, in combination with PD-1 check point blockadE, for treatment of patients with locally advaNced or metastatic adrenocortical Carcinoma, or malignant phEochromocytoma/ paRaganglioma (the Spencer study)

Reduktion postoperativer Hernien nach Laparotomien durch small stitch Bauchdeckenverschluss ohne vs. mit prophylaktischer Netzimplantation

DRKS00017517

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

A Registry for Patients With Chronic Hypoparathyroidism (PARADIGHM)

This is a prospective, observational disease and drug registry designed to evaluate the safety and effectiveness profile of rhPTH(1-84) under conditions of routine clinical practice and to observe the clinical course of chronic hypoparathyrodism. No treatment is provided as a result of participating in this registry and all decisions on the participant's treatment are determined by his or her physician.

Personalisierte Medizin für Patienten mit (fortgeschrittenen) soliden, Weichgewebs- und hämatologischen Neoplasien unter Verwendung tumorspezifischer Genpanels

Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg